Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.
Exact Sciences Corporation (EXAS) Q2 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Erik Holznecht - Manager, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Tycho Peterson - Jefferies Andrew Brackman - William Blair Catherine Schulte - Baird Matt Sykes - Goldman Sachs Dan Arias - Stifel Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Jack Meehan - Nephron Research Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Operator Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences Second Quarter 2024 Earnings Call.
The Single Best Stock to Buy Under $50
24/7 Wall Street Insights Early cancer detection is the first line of defense in preventing the disease's progression and reducing fatalities.
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Biotech Stocks You Should Know About
In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street
Exact Sciences is facing a barrage of headwinds. The company's financial results haven't been good of late.
The 3 Best Personalized Medicine Stocks to Buy in July 2024
The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected to continue expanding, with projections indicating it could reach approximately $390.65 billion, growing at a compound annual growth rate (CAGR) of around 8.20% from 2024 to 2030.
Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns
We are almost halfway through 2024, and the stock market is putting on a masterclass performance. The S&P 500 is up 12% year-to-date after rising 23% last year.
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns
With the S&P 500 sitting just a few points below setting a new all-time high, the bull market that began in 2022 is still snorting. Although a correction or even a bear market will eventually happen, the market is content to run higher.
